Higashijima Fumiaki, Hasegawa Mina, Yoshimoto Takuya, Kobayashi Yuka, Wakuta Makiko, Kimura Kazuhiro
Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Front Ophthalmol (Lausanne). 2023 Mar 1;2:1060087. doi: 10.3389/fopht.2022.1060087. eCollection 2022.
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly, affecting the macula of the retina and resulting in vision loss. There are two types of AMD, wet and dry, both of which cause visual impairment. Wet AMD is called neovascular AMD (nAMD) and is characterized by the formation of choroidal neovascular vessels (CNVs) in the macula. nAMD can be treated with intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors, which help improve vision. However, approximately half the patients do not achieve satisfactory results. Subretinal fibrosis often develops late in nAMD, leading to irreversible photoreceptor degeneration and contributing to visual loss. Currently, no treatment exists for subretinal fibrosis, and the molecular mechanisms of fibrous tissue formation following neovascular lesions remain unclear. In this review, we describe the clinical features and molecular mechanisms of macular fibrosis secondary to nAMD. Myofibroblasts play an essential role in the development of fibrosis. This review summarizes the latest findings on the clinical features and cellular and molecular mechanisms of the pathogenesis of subretinal fibrosis in nAMD and discusses the potential therapeutic strategies to control subretinal fibrosis in the future.
年龄相关性黄斑变性(AMD)是老年人失明的主要原因之一,影响视网膜黄斑并导致视力丧失。AMD有两种类型,湿性和干性,两者都会导致视力损害。湿性AMD称为新生血管性AMD(nAMD),其特征是黄斑区脉络膜新生血管(CNV)形成。nAMD可通过玻璃体内注射血管内皮生长因子(VEGF)抑制剂进行治疗,这有助于改善视力。然而,约一半的患者未取得满意疗效。视网膜下纤维化常在nAMD病程后期发生,导致不可逆的光感受器变性并造成视力丧失。目前,尚无针对视网膜下纤维化的治疗方法,新生血管病变后纤维组织形成的分子机制仍不清楚。在本综述中,我们描述了nAMD继发黄斑纤维化的临床特征和分子机制。肌成纤维细胞在纤维化发展中起重要作用。本综述总结了nAMD视网膜下纤维化发病机制的临床特征以及细胞和分子机制的最新发现,并讨论了未来控制视网膜下纤维化的潜在治疗策略。